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Bhagavat Prasad Nepal a,b
Coping with COVID-19
Severe acute respiratory syndrome corona 
virus (SARS-CoV-2) virus made its first appearance 
in Wuhan, China in December 2019. It has since 
spread like a wild fire across the globe with over five 
million corona virus disease (COVID-19) confirmed 
cases and almost three hundred fifty thousand 
deaths at the time of writing this article. This could 
however be only the tip of the iceberg considering 
the contagious nature of the SARS-CoV-2 virus and 
the rate at which it is spreading across the globe.
China did well to contain the virus with 
strict lockdown measures, sealing the affected 
areas, active case finding, tracing, tracking and 
treating the COVID-19 cases at an astonishing 
speed. In the absence of specific treatment available 
as yet, treatment consists of mainly symptomatic 
management with some experimental medications. 
Antivirals, specifically Remdesivir has been a strong 
candidate for the treatment of COVID-19.[1,2]. 
However, it has yet to receive universal acceptance 
for the treatment of COVID-19. Chloroquine and 
Hydroxychloroquine seem to be effective in limiting 
the replication of SARS-CoV-2 virus in vitro.[3]. 
COVID-19 is highly pandemic in countries where 
malaria is least prevalent and least pandemic in 
countries where malaria is highly prevalent. These 
findings suggest the hypothesis that anti-malarial 
drugs have efficacy in the treatment of COVID-19.
[4,5] Addition of zinc is believed to improve the 
efficacy of chloroquine and hydroxychloroquine 
against SARS-CoV-2.[6] Ivermectin inhibits 
SARS-CoV-2 in vitro up to 48 hours. However, 
the concentration resulting in 50% inhibition was 
found to be 35 times higher than the maximum 
plasma concentration after oral administration of the 
approved dose of Ivermectin when given fasted.[7]. 
Vitamin D lowers the viral replication rate and reduces 
the plasma concentration of pro-inflammatory 
cytokines which produce inflammation that injures 
the lining of the lungs, leading to pneumonia. This 
could possible reduce the risk of infection and death 
in COVID-19.[8,9] 
Plasma from patients recovered from 
COVID-19 that contains antibodies against SARS-
CoV-2 virus has shown promising results in patients 
with severe COVID-19.[10] This combined with 
moderate dose of corticosteroids might improve the 
outcome which might accelerate the recovery from 
COVID-19.[10]. However, use of corticosteroids for 
the treatment of COVID-19 is still far from standard 
practice.
With this perspective regarding treatment 
of COVID-19, prevention seems to be the only 
viable option against the disease. Vaccine against 
COVID-19 is being developed in several countries 
in the world with variable success.[11]. However, it 
is unlikely that it will be available any time soon 
for routine use. Alternative strategy would be to 
allow the SARS-CoV-2 to spread to increase herd 
immunity of the population. Given that the Case 
Fatality Rate (CFR) can be anything between 0.25-
3% or even more of a country’s population, the 
estimated number of people who could possibly die 
from COVID-19 may be difficult to anticipate.[12]
We are now back to square one. The preventive 
measures at present are still basically lockdown, 
physical distancing, frequent hand washing and 
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universal use of face mask along   with vigorous 
testing, tracing, tracking and treating COVID-19. If 
measures like work from home, distant education and 
public health awareness regarding the importance of 
physical distancing, hand washing and universal use 
of face mask were effectively communicated to the 
public and rigidly enforced, it would lead to decrease 
in the number of infected cases each day leading 
to flattening of the curve. These measures would 
prevent overwhelming of the scarce health care 
facilities and would also help in lifting draconian 
measures like lock down for a long time. However, 
work from home and distant education have logistic 
and realistic problems in low income country like 
Nepal. As public health authorities consider lifting 
lockdown, it is critical that robust surveillance is put 
in place. Aim of surveillance should be to limit the 
spread of disease, manage the risk of COVID-19, 
enable economic and sociable activities to resume to 
the extent possible and monitor the long-term trend 
of COVID-19 transmission.[13]
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